Harnessing immune cells to cure cancer.

Christian has been CEO of Oxford BioTherapeutics since founding the company and acquiring key technology, bioinformatics data and intellectual property. He brings more than 20 years of experience in the international biotechnology industry. Following his PhD in Pharmacology from Georgetown University, Christian worked at the US National Cancer Institute in Bethesda, Maryland. Prior to founding OBT, he held a number of positions of increasing seniority with Oxford Glycosciences, and led the company’s partnerships in oncology with Pfizer, GSK, Bayer, Wyeth, Takeda, Oxford University and the FDA.

Harald was appointed interim Chief Medical Officer in November 2022. Prior to joining OBT, he has spent the past 10 years in early clinical development oncology and has held positions of increasing seniority (as permanent employee and later as consultant) as Clinical Program Lead at MorphoSys, interim Medical Lead at Otsuka, interim Senior Medical Director at Cantargia and Celgene/BMS and as interim Vice President Clinical Science at Telix Pharmaceuticals. He served as co-founder and CMO of Volvox Therapeutics GmBH in Germany. Harald is a board-certified internist and gained his medical degree from the University of Marburg. He also holds an MBA and Master of Laws in Merges and Acquisitions.

Ben joined Oxford Biotherapeutics in 2019 and has 25 years of experience in analytical biochemistry, bioinformatics and proteomics. Previously he worked at Adaptimmune as Senior Director for Target Identification, identifying immune oncology targets for TCR-based cell therapies. Prior to that he held various positions at the University of Oxford for 15 years. Ben is Senior Director External Innovation and Operations and manages the USA and UK teams responsible for delivery of partnership programs and runs lab operations.

Lindsey joined OBT in 2011 and has held several roles within the company. She has over20 years’ experience in oncology research ranging from target discovery through to clinical studies, and prior to joining OBT, held roles at UCB, Celltech, Oxford Glycosciences and Novartis. Lindsey has inventorship on multiple patents including several for which the discovery is now part of a clinical trial. Working closely with the executive team, Lindsey leads the business development for OBT with recent successes including collaborations with Boehringer Ingelheim and Kite Pharma.

Stephen has over twenty years’ experience in intellectual property in the biotech field.  Prior to joining OBT in 2014, Stephen worked in private practice at some of the largest UK patent and trademark firms gaining a broad range of experience in worldwide patent prosecution, providing freedom to operate opinions and European opposition procedures.  Since joining OBT Stephen has been responsible for directing OBT’s global patent strategy and in providing general legal advice to senior management.

Stephen has over twenty years’ experience in intellectual property in the biotech field.  Prior to joining OBT in 2014, Stephen worked in private practice at some of the largest UK patent and trademark firms gaining a broad range of experience in worldwide patent prosecution, providing freedom to operate opinions and European opposition procedures.  Since joining OBT Stephen has been responsible for directing OBT’s global patent strategy and in providing general legal advice to senior management.

‍

Sam was appointed as Head of HR in October 2022. Prior to joining OBT, she has worked in a number of senior HR roles in a range of biotech and technology companies in recent years. Having a career in HR for more than 30 years Sam has worked for both SME and large organisations and has a passion for the development side of the HR function and supporting colleagues with unlocking employee potential and supporting the delivery of high performance practices and culture. Sam is a Chartered Member of the Institute of Personnel and Development.